Menu
paroles-d'experts-expression-rhumatismale--du-covid

Paroles d’Experts : Expression rhumatologique du COVID

IMPORTANT. Les vidéos et articles publiés ne sont pas des incitations médicales, ce sont des considérations à caractère général et non destinées à une personne en particulier ; ce sont des opinions d’experts qui participent aux débats, qu’ils soient scientifique, éthique et/ou médical. La science, la vraie, est la continuelle remise en cause des connaissances. Un consensus scientifique ne peut être que provisoire et n’a donc de légitimité que s’il est exprimé à un moment précis pour une durée limitée et, surtout, que s’il représente un compromis entre tous les courants scientifiques du moment, avec la participation d’experts pouvant avoir des avis divergents.
Les contenus de ce site ne peuvent donc pas constituer des provocations à abandonner ou à s’abstenir de suivre un traitement médical thérapeutique ou prophylactique, ni non plus des provocations à adopter des pratiques ayant une finalité thérapeutique ou prophylactique. 

Dr Gérard Guillaume
Rhumatologue, Immuno-rhumatologue

ATTENTION : CETTE VIDÉO N’EST PAS UNE PRESCRIPTION. IL FAUT DANS TOUS LES CAS EN PARLER AVEC VOTRE MÉDECIN TRAITANT.

Voir le CV du Dr Guillaume

 

Musique par Yrii Semchyshyn via Pixabay

 
Images hors interview : Footage d’archives par Fanta de Pond5 Vidéos MasterTux, Designland, Dopeoganger, Nature_Design, Paul_McManus, ChristianBodhi pour Pixabay et Hefrson pour Pond5
 

REFERENCES BIBLIOGRAPHIQUES :

  1. HAS. Les douleurs au cours des symptômes prolongés de la Covid-19. Réponses rapides, novembre 2021.
  2. Laroche F. Douleur et COVID-19. SFETD 2021
  3. Matta J, Wiernik E, Robineau O et al. COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Intern Med. Published online November 8, 2021. doi:10.1001/jamainternmed.2021.6454
  4. Garrido-Cumbrera M, Marzo-Ortega H, Christen L et al. Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). RMD Open 2021 Apr;7(1):e001546.doi: 10.1136/rmdopen-2020-001546.
  5. Clauw D, Considering the potential for an increase in chronic pain after the COVID-19 pandemic, Pain 2020, June 161: 1694-97
  6. Moore T, Bosco-Lévy P, Thurin N et al. NSAIDs and COVID-19: A Systematic Review and Meta-analysis. Drug Saf 2021 Sep;44(9):929-938. doi: 10.1007/s40264-021-01089-5.
  7. HAS. Les douleurs au cours des symptômes prolongés de la Covid-19. Réponses rapides, novembre 2021.
  8. Laroche F. Douleur et COVID-19. SFETD 2021
  9. Matta J, Wiernik E, Robineau O et al. COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Intern Med. Published online November 8, 2021. doi:10.1001/jamainternmed.2021.6454
  10. Garrido-Cumbrera M, Marzo-Ortega H, Christen L et al. Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). RMD Open 2021 Apr;7(1):e001546.doi: 10.1136/rmdopen-2020-001546.
  11. Clauw D, Considering the potential for an increase in chronic pain after the COVID-19 pandemic, Pain 2020, June 161: 1694-97
  12. Moore T, Bosco-Lévy P, Thurin N et al. NSAIDs and COVID-19: A Systematic Review and Meta-analysis. Drug Saf 2021 Sep;44(9):929-938. doi: 10.1007/s40264-021-01089-5.
  13. Pascarella Gand al :  COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020 Aug;288(2):192-206
  14. Mao L. and al : Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.  JAMA Neurol. 2020 Jun 1; 77(6):683-690.
  15. Babita Ghai and al : Telemedicine for chronic pain management during COVID-19 pandemic. Indian J Anaesth. 2020 Jun; 64(6): 456–462.
  16. Editorial : Facing up to long COVID Lancet. 2020 Dec 12;396(10266):1861.
  17. Emma Ladds, and al : Developing services for long COVID: lessons from a study of wounded healersClin Med (Lond). 2021 Jan; 21(1): 59–65
  18. Angelo Carfì  and al : Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605.
  19. Soares FHC et all: Prevalence and characteristics of new-onset pain in COVID-19 survivours, a controlled study . EurJ Pain 2021 Jul;25(6):1342-1354
  20. Ani Nalbandianet all: Post acute covid syndrome. Nature medicine2021, 27(4), 601-615
  21. Benjamin Boweet all : Postacutesequelaeof COVID-19 at 2 years. Nature Medicinevolume29,pages2347–2357 (2023)
  22.  Mayssam Nehme and all : Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting.  Annals of Internal Medicine . 6 juillet 21
  23. Johanna Rohrhoferet  all: Association between Epstein-Barr-Virus reactivation and development of Long-COVID fatigue. Allergy 2023 Jan;78(1):297-299
  24. Gold JE et all: Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation Pathogens2021,10(6), 763
  25. American Collegeof Rheumatology5-9 novembre 2021
  26. C Ferri ans all: COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series , Clinical rheumatology, 2020, 39 : 3195-3204
  27. Renin Chang and all : Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study.  E Clinical Medicine 2023 ; 56:101783
  28. ACR Convergence 2022 November 10-14, 2022. Philadelphia, PA. 
  29. Parra FG et al.ACR2022, 10-14 novembre 2022
  30. MeasePJ et al.ACR 2022, 10-14 novembre 2022
  1. Izadi Z & al.: Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19JAMA NetwOpen 1 oct. 2021, ;4(10):e2129639
  2. CloéComarmond and all : COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection. Journal of Translational Autoimmunity Volume 6, 2023, 100190
  3. Chokan Baimukhamedo and al : Arthritis after Sars Cov 2 infection. The Lancet Rheumatology. March 16, 2021
  4. IZADI Z and all : Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study.Lancet Rheumatology, 25 Juillet 2022 – thelancet.com
  5. Avouac J et all : COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study Lancet Rheumatol. 2021 Jun;3(6):e419-e426.
  6. Florence Aeschlimann et all : Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Annals of the Rheumatic Diseases Année : 2020
  7. FRENCH RMD COVID-19 COHORT (Lancet Rheumatol. 2021 Fev)
  8. Sparks JA et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann RheumDis. May 28, 2021
  9. LG Rider et all : Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. BMJ issue 7 vol 3
  10. Moore N et al : Drug Safety2020;43:611-14 DGS-urgentn°2020
  11. Liu L and allMental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality : a systematic review. E Clinical Medicine vol 40, 10111, oct 21
  12. Moore N et all : NSAIDs and COVID-19: a systematic review and meta-analysis. Drug safety, 2021
  13. Sebastian Sattui ET ALL/ Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry. American College of Rheumatology Abstract 0952
  14. Jena et al. Vaccination anti-SARS-CoV-2 : quand les maladies auto-immunes affectent les taux de séroconversion. AutoimmunRev2021 Aug30;102927.
  15. Kim : Etude CoVaPIPAD ACR2021
  16. Abhishek Abhishek et all: Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study). L ancet Respir Med. 2022 Sep;10(9):840-850.
  17. David Stahl, et all : Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis. RMD Open.2022; 8(2): e002632
  18. A Schäfer et all : ,Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis. Clinical Rheumatology vol 41, 3707-3714. AUG 15 ; 2022
  19. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. 8 février 2021.
  20. Castro da Rocha FA, Melo LDP, Berenbaum F … Tackling osteoarthritis during COVID-19 pandemic .Annals of the  Rheumatic Diseases  2021;80:151-153. …
  21. Schiavetti I, et al. Third dose of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. 38ème congrès de l’ECTRIMS, Amsterdam 26-28 octobre 2022.
  22. Rabenstein M, et al. Humoral and cellular immune responses after SARS-CoV-2-Vaccination in a Swedish cohort of persons with multiple sclerosis treated with disease modifying therapies. 38ème congrès de l’ECTRIMS, Amsterdam 26
  23. Boekel L et al. : Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies Lancet Rheumatol. 2021 Nov;3(11):e778-e788
  24. Anja Strangfeld and al : Factors associated with covid 19 relatead death in people with rheumatic disease. Ann Rheum Fis-2020-219498 on 27 January 2021.
  25. Lawson-Tovey et al. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021, 221217
  26. Stephen J. ThomasSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 2021; 385:1761-1773
  1. Fraenkel et al. Les recommandation ACR 2021 Arthritis Rheumatol 2021;73:1108-23)
  1. Résultats du registre EULAR-COVAX chez 5 121 patients : la vaccination contre le SARS-CoV-2 est sûre chez les patients atteints de rhumatismes inflammatoires et de maladies systémiques auto-immunes
  2. Latika Gupta et all : COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey ACR Convergence 2021
  3. Yan Xie et all : The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review. Front Immunol.2022; 13: 919979.
  4. Vaccination in a Swedish cohort of persons with multiple sclerosis treated with disease modifying therapies. 38ème congrès de l’ECTRIMS, Amsterdam 26-28 octobre 2022.
  5. Feuchtenberger M, Kovacs MS, Eder A, et al.. Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis. Rheumatol Int2022;42:959–66.
  6. Haberman RH, Herati R, Simon D, et al.. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis2021;80:1339–44. 10.1136/annrheumdis-2021-220597
  7. Braun-Moscovici Y, Kaplan M, Braun M, et al.. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis2021;80:1317–21. 10.1136/annrheumdis-2021-220503
  8. Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, et al.. Two-Week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann Rheum Dis 2022;81:889–97. 10.1136/annrheumdis-2021-221916
  9. Arumahandi de Silva AN et al.. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann Rheum Dis 2022;81:881–8. 10.1136/annrheumdis-2021-221876
  10. Landewé RBM et al.. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis doi: 10.1136/annrheumdis-2021-222006. 
  11. Machado PM et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31. PMID: 34972811.

  12. FeuchtenbergerM et al.  Rheumatol Int 2022 ; 42:959-66

  13. Nakafero G et al.Rheumatology2023 ; 62:1445-1450

Related Posts